Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Goldman Sachs Group Inc (GS) vs Merck & Co., Inc. (MRK) Price & Performance

Goldman Sachs Group IncTrade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Goldman Sachs Group Inc vs Merck & Co., Inc. — how do they compare? Goldman Sachs Group Inc trades at $1,042.61 (market cap $301.19B), while Merck & Co., Inc. trades at $132.88 (market cap $321.77B). The key difference: Goldman Sachs Group Inc and Merck & Co., Inc. are close in size by market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.

GSMRK
Market Cap
$301.19B$321.77B
Volume
2,592,735
Sector
FinancialsHealth
52-Week High
$1.15K$131.84
52-Week Low
$715.95$77.60
Dividend Yield
1.93%2.61%
Enterprise Value
$368.53B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Goldman Sachs Group Inc

Goldman Sachs (GS) trades at $1,034.51, down 0.49% on the day, with a neutral technical signal and strong fundamental performance. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $20.98 surpassing the $14.47 estimate. Revenue growth is robust, rising to $58.28 billion in 2025, and net income margin expanded to 31.68%. The company is positioned to benefit from a surge in investment banking activity, including leading high-profile IPOs like Anthropic.

The outlook is positive given earnings momentum and strategic positioning in key deals, but risks include volatile cash flows and high leverage. Analyst consensus is a Buy with a $1,160 price target, implying potential upside. Investors should weigh strong profitability against macroeconomic sensitivity and balance sheet pressures.

Merck & Co., Inc.

Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.

The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Goldman Sachs Group Inc

The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.

Read more on GS

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK